A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

NCT05919030 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

155

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

RADIATION: Intensity-modulated radiotherapy (IMRT)
DRUG: Tislelizumab
DRUG: Cisplatin
DRUG: Nab paclitaxel

Sponsor

Renmin Hospital of Wuhan University